Patents by Inventor Eric G. Pamer

Eric G. Pamer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240374655
    Abstract: The present disclosure describes compositions and methods for increasing the abundance of commensal bacteria belonging to the order Clostridiales, including Blautia, Ruminococcus, Clostridium, Eubacterium, Holdemania and Dorea species, that are associated with reduced lethal GVHD and improved overall survival following bone marrow or hematopoietic stem cell transplant. The present disclosure, therefore, provides methods for reducing the likelihood, incidence or severity of GVHD by (1) avoiding the loss of endogenous beneficial species through antibiotic selection; (2) by administering a therapeutically effective amount of a composition comprising one or more Clostridiales associated with reduced GVHD to individuals who may lack or have lost those strains from their intestinal microbiota.
    Type: Application
    Filed: March 15, 2024
    Publication date: November 14, 2024
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Marcel Van Den Brink, Robert Jenq, Eric G. Pamer, Ying Taur, Yusuke Shono
  • Publication number: 20240344105
    Abstract: Provided herein are biomarkers associated with mortality in COVID-19 patients. In particular, provided herein are fecal biomarkers that correlate with elevated risk of mortality in subjects suffering from COVID-19 with severe respiratory insufficiency, and methods of treating COVID-19 based thereon.
    Type: Application
    Filed: August 11, 2023
    Publication date: October 17, 2024
    Inventors: Matthew R. Stutz, Nick Dylla, Eric G. Pamer
  • Patent number: 10226443
    Abstract: Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: March 12, 2019
    Assignees: New York University, Memorial Sloan-Kettering Cancer Center, Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana (Fisabio)
    Inventors: Jose U. Scher, Carles Ubeda, Dan R. Littman, Eric G. Pamer, Steven B. Abramson, Sergei B. Koralov
  • Patent number: 10011883
    Abstract: Methods, reagents and compositions thereof for predicting RA onset in susceptible individuals, diagnosing RA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of a particular bacterial species comprising SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 (SEQ ID NO: 1+ bacteria) serves as a biomarker for the above indications.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: July 3, 2018
    Assignees: NEW YORK UNIVERSITY, MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Steven B. Abramson, Jose U. Scher, Dan R. Littman, Eric G. Pamer
  • Publication number: 20170258854
    Abstract: The present disclosure describes compositions and methods for increasing the abundance of commensal bacteria belonging to the order Clostridiales, including Blautia, Ruminococcus, Clostridium, Eubacterium, Holdemania and Dorea species, that are associated with reduced lethal GVHD and improved overall survival following bone marrow or hematopoietic stem cell transplant. The present disclosure, therefore, provides methods for reducing the likelihood, incidence or severity of GVHD by (1) avoiding the loss of endogenous beneficial species through antibiotic selection; (2) by administering a therapeutically effective amount of a composition comprising one or more Clostridiales associated with reduced GVHD to individuals who may lack or have lost those strains from their intestinal microbiota.
    Type: Application
    Filed: May 24, 2017
    Publication date: September 14, 2017
    Inventors: Marcel Van Den Brink, Robert Jenq, Eric G. Pamer, Ying Taur, Yusuke Shono
  • Publication number: 20160222436
    Abstract: Methods, reagents and compositions thereof for predicting RA onset in susceptible individuals, diagnosing RA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of a particular bacterial species comprising SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 (SEQ ID NO: 1+bacteria) serves as a biomarker for the above indications.
    Type: Application
    Filed: October 15, 2012
    Publication date: August 4, 2016
    Inventors: Steven B. ABRAMSON, Jose U. SCHER, Dan R. LITTMAN, Eric G. PAMER
  • Publication number: 20160186261
    Abstract: Methods, reagents and compositions thereof for predicting risk for NORA onset in susceptible individuals, diagnosing NORA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of at least one of SEQ ID NOs: 1-19 and/or at least one of a KO presented in either of Tables S4 or S5 serves as a biomarker for the above indications.
    Type: Application
    Filed: November 4, 2014
    Publication date: June 30, 2016
    Inventors: Jose U. Scher, Andrew Sczesnak, Randy S. Longman, Nicola Segata, Carles Ubeda, Eric G. Pamer, Steven B. Abramson, Curtis Huttenhower, Dan R. Littman, Hannah Fehlner-Peach
  • Publication number: 20160136122
    Abstract: Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein.
    Type: Application
    Filed: October 16, 2015
    Publication date: May 19, 2016
    Inventors: Jose U. Scher, Carles Ubeda, Dan R. Littman, Eric G. Pamer, Steven B. Abramson, Sergei B. Koralov
  • Publication number: 20150374760
    Abstract: Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) and psoriasis (Ps) are encompassed herein, as are methods for identifying pathogenic dysbiosis in a subject, the presence of which is a positive indicator of risk for developing PsA or of the presence of PsA in a subject with arthritic symptoms.
    Type: Application
    Filed: April 9, 2015
    Publication date: December 31, 2015
    Inventors: Jose U. Scher, Carles Ubeda, Dan R. Littman, Eric G. Pamer, Steven B. Abramson
  • Publication number: 20150167084
    Abstract: A method and an apparatus are provided for determining T-cell repertoire recovery after allo-HSCT or identifying patients at high risk of infection. Combination of 5?-RACE PCR with deep sequencing was used to quantify TCR diversity in 33 individuals using a single oligonucleotide pair. Analysis of duplicate blood samples revealed highly reproducible detection of expanded TCR clonotypes. After 6 months, recipients of cord blood grafts without anti-thymocyte globulin therapy approximated the TCR diversity of healthy subjects, whereas recipients of T-cell-depleted peripheral blood stem cell grafts had a 28-fold and 14-fold lower CD4+ and CD8+ T-cell diversity, respectively. After 12 months, these differences had leveled out for the CD4+, but not the CD8+ T-cell compartment.
    Type: Application
    Filed: July 3, 2013
    Publication date: June 18, 2015
    Inventors: Eric G. Pamer, Jeroen W. J. van Heijst, Miguel-Angel Perales, Marcel R. M. Van den Brink